Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy.

Aged Antibodies, Monoclonal, Humanized / adverse effects Antigens, CD19 Candidiasis / drug therapy Female Gastrointestinal Tract / pathology Humans Immunotherapy, Adoptive / methods Interleukin-6 Intestinal Mucosa Intestines Sepsis / drug therapy
CAR T-cell Il-6 tocilizumab

Journal

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
ISSN: 1995-9133
Titre abrégé: J Microbiol Immunol Infect
Pays: England
ID NLM: 100956211

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 04 10 2020
revised: 11 01 2021
accepted: 19 02 2021
pubmed: 14 3 2021
medline: 8 10 2021
entrez: 13 3 2021
Statut: ppublish

Résumé

We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intestinal mucosa by yeasts as IL-6 is known to be involved in mucosal wound healing.

Identifiants

DOI: 10.1016/j.jmii.2021.02.006 PMID: 33712404
pubmed: 33712404
pii: S1684-1182(21)00049-9
doi: 10.1016/j.jmii.2021.02.006
pii:
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Antigens, CD19 0
Interleukin-6 0
tocilizumab I031V2H011

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

327-330

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to declare.

Auteurs

David Beauvais (D)

Univ. Lille, CHU Lille, Department of Haematology, F-59000, Lille, France. Electronic address: david.beauvais@chru-lille.fr.

Oriane Karleskind (O)

CHU Lille, Institut de Pathologie, Centre de Biologie Pathologie Génétique, F-59000, Lille, France.

Severine Loridant (S)

Univ. Lille, Inserm U1285, CNRS UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France; CHU Lille, Service de Parasitologie Mycologie, F-59037 Lille, France.

Remy Nyga (R)

CHU Lille, Service de Parasitologie Mycologie, F-59037 Lille, France.

Marie Lamiaux (M)

CHU Lille, Institut de Pathologie, Centre de Biologie Pathologie Génétique, F-59000, Lille, France.

Anne-Sophie Moreau (AS)

CHU Lille, Critical Care Centre, F-59000, Lille, France.

Franck Morschhauser (F)

Univ. Lille, CHU Lille, Department of Haematology, F-59000, Lille, France.

Suman Mitra (S)

University of Lille, Inserm, UMR-S 1172, F-59000, Lille, France.

Ibrahim Yakoub-Agha (I)

Univ. Lille, CHU Lille, Department of Haematology, F-59000, Lille, France; University of Lille, CHU Lille, Inserm, Infinite, U1286, F-59000 Lille, France.

Boualem Sendid (B)

Univ. Lille, Inserm U1285, CNRS UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France; CHU Lille, Service de Parasitologie Mycologie, F-59037 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Potential role of tocilizumab in severe...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Potential role of tocilizumab in severe...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes B › Antigènes CD19 › Potential role of tocilizumab in severe...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Mycoses › Candidose › Potential role of tocilizumab in severe...
questionsmedicales.fr › Système digestif › Tube digestif › Potential role of tocilizumab in severe...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Potential role of tocilizumab in severe...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Immunothérapie adoptive › Potential role of tocilizumab in severe...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-6 › Potential role of tocilizumab in severe...
questionsmedicales.fr › Tissus › Membranes › Muqueuse › Muqueuse intestinale › Potential role of tocilizumab in severe...
questionsmedicales.fr › Système digestif › Tube digestif › Intestins › Potential role of tocilizumab in severe...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Potential role of tocilizumab in severe...